Silvio Abati

Prof. Silvio Abati

Vita-Salute San Raffaele University, Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
SASilvio Abati
Silvio Abati
CBChiara Bramati
Chiara Bramati
SBStefano Bondi
Stefano Bondi
Alessandra LissoniAlessandra Lissoni
Alessandra Lissoni
Matteo TrimarchiMatteo Trimarchi
Matteo Trimarchi
Oral cancer (OC) is an uncommon malignancy in Western countries, being one of the most common cancers in some high-risk areas of the world. It is a largely preventable cancer, since most of the different risk factors identified, such as tobacco use, alcohol consumption, and betel nut chewing, are behaviors that increase the likelihood of the disease. Given its high mortality, early diagnosis is of utmost importance. Prevention and the anticipation of diagnosis begin with identification of potentially malignant lesions of the oral mucosa and with local conditions promoting chronic inflammation. Therefore, every lesion must be recognized promptly and treated adequately. The clinical recognition and evaluation of oral mucosal lesions can detect up to 99% of oral cancers/premalignancies. As stated by the World Health Organization, any suspicious lesion that does not subside within two weeks from detection and removal of local causes of irritation must be biopsied. Surgical biopsy remains the gold standard for diagnosis of oral cancer. Adjunctive tools have been developed and studied to help clinicians in the diagnostic pathway, such as toluidine blue vital staining and autofluorescence imaging. In the near future other methods, i.e., identification of salivary markers of progression may help in reducing mortality due to oral cancer.

1 December 2014 in Therapeutics and Clinical Risk Management
Verified
Journal Article
Open access
AVAlessandro Villa
Alessandro Villa
CCChristopher Connell
Christopher Connell
SASilvio Abati
Silvio Abati
Diagnosis and management of xerostomia and hyposalivation Alessandro Villa,1,2 Christopher L Connell,3 Silvio Abati4 1Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA; 3Department of General Dentistry, Boston University Henry M Goldman School of Dental Medicine, Boston, MA, USA; 4Dental Clinic, Department of Health Sciences, University of Milan, Milano, Italy Xerostomia, the subjective complaint of dry mouth, and hyposalivation remain a significant burden for many individuals. Diagnosis of xerostomia and salivary gland hypofunction is dependent upon a careful and detailed history and thorough oral examination. There exist many options for treatment and symptom management: salivary stimulants, topical agents, saliva substitutes, and systemic sialogogues. The aim of this review is to investigate the current state of knowledge on management and treatment of patients affected by xerostomia and/or hyposalivation.

1 August 1999 in Clinical Oral Implants Research
Verified
Journal Article
Closed access
PDF file
MCMatteo Chiapasco
Matteo Chiapasco
SASilvio Abati
Silvio Abati
EREugenio Romeo
Eugenio Romeo
GVGiorgio Vogel
Giorgio Vogel

28 August 2011 in Australian Dental Journal
Verified
Journal Article
Closed access
PDF file
AVAlessandro Villa
Alessandro Villa
SASilvio Abati
Silvio Abati

10 July 2011 in Australian Dental Journal
Verified
Journal Article
Closed access
PDF file
AVAlessandro Villa
Alessandro Villa
CVC Villa
C Villa
SASilvio Abati
Silvio Abati

1 July 2011 in The Journal of the American Dental Association
Verified
Journal Article
Closed access
AVAlessandro Villa
Alessandro Villa
APAntonella Polimeni
Antonella Polimeni
LSLaura Strohmenger
Laura Strohmenger
DCDomenico Cicciù
Domenico Cicciù
GEGherlone Felice Enrico
Gherlone Felice Enrico
SASilvio Abati
Silvio Abati